Drug Discovery

Target Identification vs Target Validation in Drug Discovery

Published 2026-08-22 · Updated 2026-08-22

Answer in brief

Before funding deeper validation, Target Identification vs Target Validation in Drug Discovery should resolve whether the program is still generating candidates or testing a specific target thesis. The minimum credible analysis compares distinct routes using candidate breadth, causal evidence, perturbation data, assay readiness, translational bridge, and validation ownership and attempts to state the result that would make the target lose against a named alternative. The result should name the leading direction, the counterevidence, and the condition that would stop it.

Evidence status: Decision-method guide; not a completed investigation or final validation.

The decision this guide supports

whether the program is still generating candidates or testing a specific target thesis

Why the problem is difficult

The article-specific identification challenge is whether the question “whether the program is still generating candidates or testing a specific target thesis” can be resolved using candidate breadth, causal evidence, perturbation data, assay readiness, translational bridge, and validation ownership, rather than merely restated in new language.

A falsifier-first workflow

  • Define the decision precisely: whether the program is still generating candidates or testing a specific target thesis.
  • Build a source and data ledger around candidate breadth, causal evidence, perturbation data, assay readiness, translational bridge, and validation ownership.
  • Compare the inherited route with a mechanistically distinct alternative and a constraint-based null.
  • Actively search for the strongest counterevidence relevant to this decision, including boundary cases and prior failures.
  • Run the lowest-cost discriminating challenge: state the result that would make the target lose against a named alternative.
  • Record pursue, reframe, or stop, the confidence level, the evidence ceiling, and who owns downstream validation.

Decision criteria

  • Decision impact: would the result materially change the choice about whether the program is still generating candidates or testing a specific target thesis?
  • Evidence fit: does the available evidence—candidate breadth, causal evidence, perturbation data, assay readiness, translational bridge, and validation ownership—directly address the decision rather than merely correlate with it?
  • Discrimination: does the preferred route predict an outcome a credible alternative does not?
  • Robustness: does the ranking survive the challenge “state the result that would make the target lose against a named alternative”?
  • Validation boundary: is the conclusion no stronger than the available sources, data and computation?

Supporting evidence

candidate breadth, causal evidence, perturbation data, assay readiness, translational bridge, and validation ownership

Counterevidence

For this decision, a result from “state the result that would make the target lose against a named alternative” that reverses or flattens the ranking must remain visible even when it is commercially inconvenient.

Computation

Here computation earns its place only if it changes the choice about whether the program is still generating candidates or testing a specific target thesis or exposes why the available evidence cannot resolve it.

Fastest falsifier

state the result that would make the target lose against a named alternative

When to stop or reframe

A decision-specific stop trigger is failure of the challenge “state the result that would make the target lose against a named alternative” without an independently supported alternative mechanism.

Evidence ceiling

Identification evidence should not be written as validation.

Sources and starting points

  • Open Targets Platform — Integrated public evidence connecting therapeutic targets and diseases.
  • ChEMBL — Curated bioactivity information for compounds, assays, and targets.
  • ClinicalTrials.gov — Official registry and results database for clinical studies; registry records are not proof of efficacy.
  • PubMed — Primary biomedical literature discovery; individual studies require direct appraisal.
  • AlphaFold Protein Structure Database — Additional authoritative starting point selected for this decision area; applicability must be checked against the precise question.
  • Europe PMC — Additional authoritative starting point selected for this decision area; applicability must be checked against the precise question.

Continue the decision journey

  1. Drug Target Prioritization: A Falsifier-First Framework
  2. What Counts as Evidence for Drug Target Validation?
  3. Map the Translational Gap Before Advancing a Drug Program

Explore the full topic hub · Editorial standard · Scientific Oracle consulting

Frequently asked questions

What decision does “Target Identification vs Target Validation in Drug Discovery” help make?
It supports a bounded decision about whether the program is still generating candidates or testing a specific target thesis. The framework keeps alternatives, evidence, counterevidence, uncertainty, and the fastest falsification test visible.
What is the fastest useful test?
state the result that would make the target lose against a named alternative
Can computation validate the final scientific claim?
No. Identification evidence should not be written as validation. Computation can prioritize and eliminate directions; final validation remains with the appropriate domain methods and accountable specialists.
When should the project stop or reframe?
Stop or reframe when the target-disease link is not robust, the mechanism lacks a discriminating prediction, tractability depends on unsupported assumptions, public data contradict the thesis, or the next credible validation belongs in a qualified experimental program.